Peripheral neuropathy decisions — 2025

The Veteran's claim for specially adapted housing was denied as he does not meet the criteria due to his ability to independently ambulate with the use of braces.

The Board granted service connection for diabetes mellitus, type II, coronary artery disease (CAD), and bilateral upper extremity peripheral neuropathy.

The Board granted service connection for neuropathy of the left and right upper extremities as secondary to diabetes mellitus, and hypertension prior to August 10, 2022, due to in-service exposure to herbicide agents. The claim for an acquired psychiatric disorder including depression was remanded.

The Board granted service connection for bilateral ischemic optic neuropathy, resolving reasonable doubt in the Veteran's favor.

The Board granted the petitions to readjudicate claims for service connection for bilateral hearing loss and an acquired psychiatric disability, while denying service connection for lower back, kidney, diabetes mellitus type II, hypertension, left lower extremity peripheral neuropathy, right lower extremity peripheral neuropathy, and sleep apnea.

The Board dismissed all service connection claims due to the Veteran's death, as there is no substituted appellant for this appeal.

The Board remands the claims for service connection for colon cancer, abdominal scar status post bowel resection, and chemotherapy-induced peripheral neuropathy due to inadequate VA examination opinions.

The Board granted a rating of 20 percent for the Veteran's left lower extremity diabetic peripheral neuropathy associated with herbicide agent exposure, resolving all doubt in favor of the Veteran.

The Board denied readjudication of increased rating claims for diabetes mellitus, bilateral knee, bilateral lower extremity peripheral neuropathy, and cervical spine, as well as an earlier effective date for DEA and entitlement to TDIU due to the lack of new and relevant evidence.

The Board denied evaluations in excess of 10 percent for neuropathy and a compensable rating for hypertension, as well as an evaluation in excess of 20 percent for diabetes mellitus type II.

The Board denied service connection for a vision disability, an upper body rash, and a right hand disability as the evidence did not support a finding that any of these conditions were related to the Veteran's active duty service.

The Board granted ratings of 30 to 40 percent for various diabetic neuropathies and restored a 10 percent rating for hypertension, while denying an increased rating for diabetes mellitus type II.

The Board dismissed the veteran's appeals for service connection for various conditions, including foot and calf pain, hammertoes, hallux valgus, and cervical spine degenerative arthritis.

The Veteran is granted a total disability rating based on individual unemployability (TDIU) and an effective date of August 13, 2019, for the grant of Special Monthly Compensation (SMC) based on the need for aid and attendance.

The Board granted an effective date of December 8, 2017, for the grant of service connection for rhinitis but denied initial compensable ratings and higher ratings for other conditions.

The Board granted service connection for bilateral upper and lower extremity peripheral neuropathy, secondary to diabetes mellitus type II.

The Board granted earlier effective dates of January 10, 2017, for the award of service connection for voiding dysfunction and peripheral neuropathy in all extremities.

The Board granted service connection for a right knee disability and denied service connection for right shoulder scars. The claims for peripheral neuropathy of the left thumb, a right ankle disorder, and a left ankle disorder were remanded.

The Board dismissed the appeal for earlier effective dates of service connection for various peripheral neuropathies due to a prohibited concurrent election.

The Board granted service connection for GERD, left and right upper extremity peripheral neuropathy, left and right lower extremity peripheral neuropathy, emphysema, and COPD.